Can we all agree that PP405 is now 4 years away 8/20/2025
PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Prepare to be disappointed by PP405
Delayed release oral minoxidil is seen as a promising advancement for hair loss treatment, offering safer, higher doses and more consistent hair follicle stimulation compared to current options. However, it is not expected to replace finasteride or dutasteride, as it does not prevent androgenetic alopecia.
community PP405 is a game changer. One for the history books. Era defining moment and Pelage know it.
PP405 is a new hair loss treatment that may outperform minoxidil and finasteride by growing thick hair in bald areas within four weeks. Its release is expected around 2028, but concerns about its long-term efficacy and cost remain.
community Pelage PP405: New Hair Growth from Inactive Follicular Units - Phase 2a results at AAD 2026
PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.
community Most Promising Future Hair Loss Treatments In 2026
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
community My Hair Loss Protocol - Actually works!!!
A 22-year-old man experienced significant hair regrowth using a combination of biotin supplements, Hims topical finasteride + minoxidil solution, a microneedling pen, 0.5 mg dutasteride, and topical PP405 solution. Despite skepticism about PP405's effectiveness, he claims this regimen worked for him after previous treatments failed.
Related Research
6 / 6 resultsresearch Emerging pharmacotherapies for Androgenetic Alopecia
This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
research A single-center, prospective, open-label, pilot study of the safety, local tolerability, and efficacy of ultraviolet-C (UVC) phototherapy for the treatment of great toenail onychomycosis
Trichoscopy is a helpful and quick method to diagnose hair loss without shaving.
research Hair loss: An epidemiologic approach
Hair loss affects 20% of people, more in men and those over 35, and is often associated with a sensitive scalp.
research Clinical interest of a nonchemical lotion in head lice management
A nonchemical lotion was found effective in killing head lice and their eggs in most people, indicating it could be useful for managing head lice.
research Trichoscopy: Usefulness in diagnosing hair loss in adult female patients
Trichoscopy is a helpful and quick method to identify different types of hair loss in women.
research PP405 in Alopecia: An Emerging Molecule worth Investigating
In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.